Wall Street analysts expect Prestige Consumer Healthcare (PBH) to post quarterly earnings of $1.44 per share in its upcoming report, which indicates a year-over-year increase of 9.1%. Revenues are expected to be $294.29 million, down 0.8% from the year-ago quarter.
The consensus EPS estimate for the quarter has been revised 1.9% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Prestige Consumer Healthcare metrics that are commonly monitored and projected by Wall Street analysts.
The average prediction of analysts places 'Revenues- OTC Healthcare- International' at $47.65 million. The estimate indicates a change of +0.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- OTC Healthcare- North American' should come in at $245.89 million. The estimate points to a change of -1.2% from the year-ago quarter.
Analysts' assessment points toward 'Gross profit- OTC Healthcare- North American' reaching $142.40 million. The estimate compares to the year-ago value of $141.49 million.
Analysts expect 'Gross profit- OTC Healthcare- International' to come in at $27.92 million. The estimate is in contrast to the year-ago figure of $28.52 million.
View all Key Company Metrics for Prestige Consumer Healthcare here>>>Over the past month, shares of Prestige Consumer Healthcare have returned -3.8% versus the Zacks S&P 500 composite's +11% change. Currently, PBH carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Prestige Consumer Healthcare Inc. (PBH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).